Yifan Xinfu Pharmaceutical Co Ltd

Yifan Pharmaceutical released its 2026 interim report. Net profit attributable to the parent in the first half was 205 million yuan, down 32.5% year on year. Operating revenue was 2.47 billion yuan, down 6.4% year on year. Net profit attributable to the parent after deducting non-recurring items was 203 million yuan, down 14.4% year on year. Net operating cash flow was 594 million yuan, up 107.5% year on year. In the second quarter, operating revenue was 1.21 billion yuan, down 7.4% year on year, and net profit attributable to the parent was 98.2 million yuan, down 34.7% year on year. As of the end of the second quarter, total assets were 12.888 billion yuan, up 0.3% from the end of the previous year, and net assets attributable to the parent were 8.847 billion yuan, up 0.1% from the end of the previous year. The company said its main operating business had not undergone any major changes. Sales volume of vitamin B5 products increased, but prices fluctuated in the short term due to geopolitical factors. The company plans not to distribute cash dividends, not to issue bonus shares, and not to convert capital reserve into share capital.

Baiyunshan's wholly-owned subsidiary Mingxing Pharmaceutical has passed the generic drug quality and efficacy consistency evaluation for its norepinephrine bitartrate injection. The drug, with a specification of 1ml:2mg, was approved for marketing in 1982 and is used for blood pressure control in certain acute hypotensive states. Mingxing Pharmaceutical submitted its consistency evaluation application on April 16, 2025, and it was accepted on April 30. According to Menet data, domestic sales of this drug in 2025 were approximately 769 million yuan, with major manufacturers including Grand Pharmaceutical, Hefei Yifan Biotech, and Tianjin Jinyao Pharmaceutical. Mingxing Pharmaceutical's R&D investment for this consistency evaluation was approximately 1.2557 million yuan.